Regeneron Pharmaceuticals, Inc.
Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

Last updated:

Abstract:

The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.

Status:
Grant
Type:

Utility

Filling date:

9 Aug 2018

Issue date:

24 Aug 2021